The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment

Therapeutic implications

Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, Giovanni Tonon, Ursula Hainz, Yu Tzu Tai, Sonia Vallet, Niels Halama, Dirk Jäger, Dian L. Olson, Martin Sattler, Dharminder Chauhan, Kenneth C. Anderson

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Recent advances regarding the introduction of anti-adhesion strategies as a novel therapeutic concept in oncology hold great promise. Here we evaluated the therapeutic potential of the new-in-class-molecule selective-adhesion-molecule (SAM) inhibitor Natalizumab, a recombinant humanized IgG4 monoclonal antibody, which binds integrin-α4, in multiple myeloma (MM). Natalizumab, but not a control antibody, inhibited adhesion of MM cells to non-cellular and cellular components of the microenvironment as well as disrupted the binding of already adherent MM cells. Consequently, Natalizumab blocked both the proliferative effect of MM-bone marrow (BM) stromal cell interaction on tumour cells, and vascular endothelial growth factor (VEGF)-induced angiogenesis in the BM milieu. Moreover, Natalizumab also blocked VEGF- and insulin-like growth factor 1 (IGF-1)-induced signalling sequelae triggering MM cell migration. In agreement with our in vitro results, Natalizumab inhibited tumour growth, VEGF secretion, and angiogenesis in a human severe combined immunodeficiency murine model of human MM in the human BM microenvironment. Importantly, Natalizumab not only blocked tumour cell adhesion, but also chemosensitized MM cells to bortezomib, in an in vitro therapeutically representative human MM-stroma cell co-culture system model. Our data therefore provide the rationale for the clinical evaluation of Natalizumab, preferably in combination with novel agents (e.g. bortezomib) to enhance MM cytotoxicity and improve patient outcome.

Original languageEnglish
Pages (from-to)438-448
Number of pages11
JournalBritish Journal of Haematology
Volume155
Issue number4
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Multiple Myeloma
Bone Marrow
Growth
Vascular Endothelial Growth Factor A
Therapeutics
Cellular Microenvironment
Antibodies, Monoclonal, Humanized
Natalizumab
Severe Combined Immunodeficiency
Neoplasms
Somatomedins
Coculture Techniques
Mesenchymal Stromal Cells
Cell Adhesion
Integrins
Cell Communication
Cell Movement
Cell Culture Techniques
Immunoglobulin G
Antibodies

Keywords

  • Adhesion
  • Bone marrow microenvironment
  • Cell adhesion-mediated drug resistance
  • Integrin-α4
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment : Therapeutic implications. / Podar, Klaus; Zimmerhackl, Alexander; Fulciniti, Mariateresa; Tonon, Giovanni; Hainz, Ursula; Tai, Yu Tzu; Vallet, Sonia; Halama, Niels; Jäger, Dirk; Olson, Dian L.; Sattler, Martin; Chauhan, Dharminder; Anderson, Kenneth C.

In: British Journal of Haematology, Vol. 155, No. 4, 11.2011, p. 438-448.

Research output: Contribution to journalArticle

Podar, K, Zimmerhackl, A, Fulciniti, M, Tonon, G, Hainz, U, Tai, YT, Vallet, S, Halama, N, Jäger, D, Olson, DL, Sattler, M, Chauhan, D & Anderson, KC 2011, 'The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications', British Journal of Haematology, vol. 155, no. 4, pp. 438-448. https://doi.org/10.1111/j.1365-2141.2011.08864.x
Podar, Klaus ; Zimmerhackl, Alexander ; Fulciniti, Mariateresa ; Tonon, Giovanni ; Hainz, Ursula ; Tai, Yu Tzu ; Vallet, Sonia ; Halama, Niels ; Jäger, Dirk ; Olson, Dian L. ; Sattler, Martin ; Chauhan, Dharminder ; Anderson, Kenneth C. / The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment : Therapeutic implications. In: British Journal of Haematology. 2011 ; Vol. 155, No. 4. pp. 438-448.
@article{c29fe15e180a496391d55090067c69d0,
title = "The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications",
abstract = "Recent advances regarding the introduction of anti-adhesion strategies as a novel therapeutic concept in oncology hold great promise. Here we evaluated the therapeutic potential of the new-in-class-molecule selective-adhesion-molecule (SAM) inhibitor Natalizumab, a recombinant humanized IgG4 monoclonal antibody, which binds integrin-α4, in multiple myeloma (MM). Natalizumab, but not a control antibody, inhibited adhesion of MM cells to non-cellular and cellular components of the microenvironment as well as disrupted the binding of already adherent MM cells. Consequently, Natalizumab blocked both the proliferative effect of MM-bone marrow (BM) stromal cell interaction on tumour cells, and vascular endothelial growth factor (VEGF)-induced angiogenesis in the BM milieu. Moreover, Natalizumab also blocked VEGF- and insulin-like growth factor 1 (IGF-1)-induced signalling sequelae triggering MM cell migration. In agreement with our in vitro results, Natalizumab inhibited tumour growth, VEGF secretion, and angiogenesis in a human severe combined immunodeficiency murine model of human MM in the human BM microenvironment. Importantly, Natalizumab not only blocked tumour cell adhesion, but also chemosensitized MM cells to bortezomib, in an in vitro therapeutically representative human MM-stroma cell co-culture system model. Our data therefore provide the rationale for the clinical evaluation of Natalizumab, preferably in combination with novel agents (e.g. bortezomib) to enhance MM cytotoxicity and improve patient outcome.",
keywords = "Adhesion, Bone marrow microenvironment, Cell adhesion-mediated drug resistance, Integrin-α4, Multiple myeloma",
author = "Klaus Podar and Alexander Zimmerhackl and Mariateresa Fulciniti and Giovanni Tonon and Ursula Hainz and Tai, {Yu Tzu} and Sonia Vallet and Niels Halama and Dirk J{\"a}ger and Olson, {Dian L.} and Martin Sattler and Dharminder Chauhan and Anderson, {Kenneth C.}",
year = "2011",
month = "11",
doi = "10.1111/j.1365-2141.2011.08864.x",
language = "English",
volume = "155",
pages = "438--448",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment

T2 - Therapeutic implications

AU - Podar, Klaus

AU - Zimmerhackl, Alexander

AU - Fulciniti, Mariateresa

AU - Tonon, Giovanni

AU - Hainz, Ursula

AU - Tai, Yu Tzu

AU - Vallet, Sonia

AU - Halama, Niels

AU - Jäger, Dirk

AU - Olson, Dian L.

AU - Sattler, Martin

AU - Chauhan, Dharminder

AU - Anderson, Kenneth C.

PY - 2011/11

Y1 - 2011/11

N2 - Recent advances regarding the introduction of anti-adhesion strategies as a novel therapeutic concept in oncology hold great promise. Here we evaluated the therapeutic potential of the new-in-class-molecule selective-adhesion-molecule (SAM) inhibitor Natalizumab, a recombinant humanized IgG4 monoclonal antibody, which binds integrin-α4, in multiple myeloma (MM). Natalizumab, but not a control antibody, inhibited adhesion of MM cells to non-cellular and cellular components of the microenvironment as well as disrupted the binding of already adherent MM cells. Consequently, Natalizumab blocked both the proliferative effect of MM-bone marrow (BM) stromal cell interaction on tumour cells, and vascular endothelial growth factor (VEGF)-induced angiogenesis in the BM milieu. Moreover, Natalizumab also blocked VEGF- and insulin-like growth factor 1 (IGF-1)-induced signalling sequelae triggering MM cell migration. In agreement with our in vitro results, Natalizumab inhibited tumour growth, VEGF secretion, and angiogenesis in a human severe combined immunodeficiency murine model of human MM in the human BM microenvironment. Importantly, Natalizumab not only blocked tumour cell adhesion, but also chemosensitized MM cells to bortezomib, in an in vitro therapeutically representative human MM-stroma cell co-culture system model. Our data therefore provide the rationale for the clinical evaluation of Natalizumab, preferably in combination with novel agents (e.g. bortezomib) to enhance MM cytotoxicity and improve patient outcome.

AB - Recent advances regarding the introduction of anti-adhesion strategies as a novel therapeutic concept in oncology hold great promise. Here we evaluated the therapeutic potential of the new-in-class-molecule selective-adhesion-molecule (SAM) inhibitor Natalizumab, a recombinant humanized IgG4 monoclonal antibody, which binds integrin-α4, in multiple myeloma (MM). Natalizumab, but not a control antibody, inhibited adhesion of MM cells to non-cellular and cellular components of the microenvironment as well as disrupted the binding of already adherent MM cells. Consequently, Natalizumab blocked both the proliferative effect of MM-bone marrow (BM) stromal cell interaction on tumour cells, and vascular endothelial growth factor (VEGF)-induced angiogenesis in the BM milieu. Moreover, Natalizumab also blocked VEGF- and insulin-like growth factor 1 (IGF-1)-induced signalling sequelae triggering MM cell migration. In agreement with our in vitro results, Natalizumab inhibited tumour growth, VEGF secretion, and angiogenesis in a human severe combined immunodeficiency murine model of human MM in the human BM microenvironment. Importantly, Natalizumab not only blocked tumour cell adhesion, but also chemosensitized MM cells to bortezomib, in an in vitro therapeutically representative human MM-stroma cell co-culture system model. Our data therefore provide the rationale for the clinical evaluation of Natalizumab, preferably in combination with novel agents (e.g. bortezomib) to enhance MM cytotoxicity and improve patient outcome.

KW - Adhesion

KW - Bone marrow microenvironment

KW - Cell adhesion-mediated drug resistance

KW - Integrin-α4

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=80054991119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054991119&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08864.x

DO - 10.1111/j.1365-2141.2011.08864.x

M3 - Article

VL - 155

SP - 438

EP - 448

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -